Loading...
•
Mar 31, 2021
Kodiak Sciences Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Kodiak Sciences reported a net loss of $50.4 million for the first quarter of 2021, with R&D expenses increasing to $40.3 million due to higher clinical trial costs for KSI-301. The company ended the quarter with $929.0 million in cash, cash equivalents, and marketable securities.
DAZZLE study is fully enrolled.
RVO and DME pivotal studies are all recruiting globally.
DAYLIGHT study will evaluate monthly dosing of KSI-301 in patients with wet AMD.
Construction of the manufacturing facilities is now targeted for completion in early 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...